Anne Wojcicki is sitting on a treasure trove of genetic data. The co-founder and chief executive of 23andMe has led the genetic testing company through 14 years in which it has collected data from millions of customers through their at-home DNA spit test kits. In 2018, the company announced a collaboration with GlaxoSmithKline to use this anonymized, aggregated data to develop new pharmaceutical drugs and attracted a $300 million investment from the pharmaceutical giant. And in June, when Wojcicki took the company public, it was valued at $3.5 billion. In some ways, its a standard Silicon Valley play: Lure customers in with the promise of democratizing information before quickly moving to monetize that information. But what are the implications when the information at stake is your DNA?<\/p>\n
[You can listen to this episode of Sway on Apple, Spotify, Google or wherever you get your podcasts.]<\/p>\n
In this conversation, Kara presses Wojcicki on the ethical, privacy and security questions intertwined with the 23andMe business model. They discuss what the rise of genetic testing might mean for todays 2-year-olds and how the United States is faring in a genetic information race with China. And they dig into the ongoing Theranos trial specifically, whether the case against Elizabeth Holmes will rein in a Silicon Valley health tech sector that, in the past, has run a little wild.<\/p>\n
(A full transcript of the episode will be available midday on the Times website.)<\/p>\n
Thoughts? Email us at sway@nytimes.com<\/a>.<\/p>\n Sway is produced by Nayeema Raza, Blakeney Schick, Matt Kwong, Daphne Chen and Caitlin OKeefe, and edited by Nayeema Raza; fact-checking by Kate Sinclair; music and sound design by Isaac Jones; mixing by Carole Sabouraud and Sonia Herrero; audience strategy by Shannon Busta. Special thanks to Kristin Lin and Liriel Higa.<\/p>\n <\/p>\n Read this article: Anne Wojcicki is sitting on a treasure trove of genetic data. The co-founder and chief executive of 23andMe has led the genetic testing company through 14 years in which it has collected data from millions of customers through their at-home DNA spit test kits. In 2018, the company announced a collaboration with GlaxoSmithKline to use this anonymized, aggregated data to develop new pharmaceutical drugs and attracted a $300 million investment from the pharmaceutical giant. Continue reading
\nOpinion | What Is 23andMe Doing With Your DNA? - The New York Times<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"